Broncus Holding Full Year 2024 Earnings: US$0.031 loss per share (vs US$0.057 loss in FY 2023)

Broncus Holding (HKG:2216) Full Year 2024 Results

Key Financial Results

• Net loss: US$15.3m (loss narrowed by 46% from FY 2023).
• US$0.031 loss per share (improved from US$0.057 loss in FY 2023).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Broncus Holding Earnings Insights

The primary driver behind last 12 months revenue was the Mainland China segment contributing a total revenue of US$3.21m (40% of total revenue). The largest operating expense was Research & Development (R&D) costs, amounting to US$11.5m (40% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of US$7.19m. Explore how 2216's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in Hong Kong.

Performance of the Hong Kong Medical Equipment industry.

The company's shares are up 38% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 1 warning sign for Broncus Holding you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.